Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer

Marla Lipsyc-Sharf; Elza C. de Bruin; Katheryn Santos; Robert McEwen; Daniel Stetson; Ashka Patel; Gregory J. Kirkner; Melissa E. Hughes; Sara M. Tolaney; Ann H. Partridge; Ian E. Krop; Charlene Knape; Ute Feger; Giovanni Marsico; Karen Howarth; Eric P. Winer; Nancy U. Lin; Heather A. Parsons

doi:10.1200/jco.22.00908

Abstract

In this prospective study, in patients with high-risk HR+ BC in the late adjuvant setting, ctDNA was identified a median of 1 year before all cases of distant metastasis. Future studies will determine if ctDNA-guided intervention in patients with HR+ BC can alter clinical outcomes.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lipsyc-Sharf et al. (2022) studied this question.

synapsesocial.com/papers/69d7e9bf05ee2ba81dbee86b https://doi.org/10.1200/jco.22.00908

View Full Paper

Ask AI

Bookmark

Share

Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer

Abstract

Discussion

Cite This Study

Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Journal of Clinical Oncology

Keep reading

More related papers

More from Journal of Clinical Oncology